ReviewBiomolecules2021
New Avenues for Parkinson's Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Inflammatory microbes and genes as potential biomarkers of Parkinson's disease.NPJ biofilms and microbiomes · 2022Pooled it
- Gut microbiota as a modulator of HDAC: insights into Alzheimer's disease treatment.Pharmacological reports : PR · 2026Review
- Emerging insight in genetics and therapies in young-onset Parkinson's disease (YOPD): a comprehensive review.Journal of neurology · 2026Review
- Silent Intruders: The Gut Virome in Brain Aging and Cognitive Decline.Pathogens (Basel, Switzerland) · 2026Review
- Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- The Aging Gut-Brain Axis: Effects of Dietary Polyphenols and Metal Exposure.Chronic diseases and translational medicine · 2025Review
- Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.Marine drugs · 2025Review
- Reduced levels of nitrated α-synuclein in the protective effect of harpagoside on rotenone-induced cellular models of Parkinson's disease.Frontiers in cell and developmental biology · 2025Article
- Food for thought: probiotic modulation of microglial activity in Parkinson's disease.Frontiers in molecular neuroscience · 2025Review
- Gut Microbiome and Its Role in Parkinson's Disease.Cureus · 2024Review
- Cold-pressed perilla seed oil: Investigating its protective influence on the gut-brain axis in mice with rotenone-induced Parkinson's disease.Food science & nutrition · 2024Article
- The Gut Microbiome as a Catalyst and Emerging Therapeutic Target for Parkinson's Disease: A Comprehensive Update.Biomedicines · 2024Review
- Gut-brain axis and neurodegeneration: mechanisms and therapeutic potentials.Frontiers in neuroscience · 2024Review
- The role of the gut microbiota in neurodegenerative diseases targeting metabolism.Frontiers in neuroscience · 2024Review
- Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies.Translational neurodegeneration · 2023Review
- Targeting the Gut-Brain Axis with Fecal Microbiota Transplantation: Considerations on a Potential Novel Treatment for Parkinson's Disease.Movement disorders clinical practice · 2023Article
- Calprotectin, Biomarker of Depression in Patients with Inflammatory Bowel Disease?Medicina (Kaunas, Lithuania) · 2023Article
- The brain-gut-microbiota axis in the treatment of neurologic and psychiatric disorders.Arquivos de neuro-psiquiatria · 2023Review
- Pathways to healing: Plants with therapeutic potential for neurodegenerative diseases.IBRO neuroscience reports · 2023Article
- Probiotics for Neurodegenerative Diseases: A Systemic Review.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease (PD) is a multifactorial neurodegenerative disorder that currently affects 1% of the population over the age of 60 years, and for which no disease-modifying treatments exist. Neurodegeneration and neuropathology in different brain areas are manifested as both motor and non-motor symptoms in patients. Recent interest in the gut-brain axis has led to increasing research into the gut microbiota changes in PD patients and their impact on disease pathophysiology. As evidence is piling up on the effects of gut microbiota in disease development and progression, another front of action has opened up in relation to the potential usage of microbiota-based therapeutic strategies in treating gastrointestinal alterations and possibly also motor symptoms in PD. This review provides status on the different strategies that are in the front line (i.e., antibiotics; probiotics; prebiotics; synbiotics; dietary interventions; fecal microbiota transplantation, live biotherapeutic products), and discusses the opportunities and challenges the field of microbiome research in PD is facing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.